Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)

Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classifica...

Full description

Bibliographic Details
Main Authors:	Josephine Lucero, Salman Al-Harbi, Karen W. L. Yee
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	Current Oncology
Subjects:	myelodysplastic neoplasm prognostic scoring system lenalidomide luspatercept antithymocyte globulin hypomethylating agent
Online Access:	https://www.mdpi.com/1718-7729/30/7/459

Similar Items

Myelodysplastic syndromes: therapeutic problems and decisions (review)
by: S. V. Semochkin, et al.
Published: (2014-07-01)

Myelodysplastic syndromes: therapeutic problems and decisions (review)
by: S. V. Semochkin, et al.
Published: (2014-07-01)

Targeting the Microenvironment in MDS: The Final Frontier
by: Patric Teodorescu, et al.
Published: (2020-07-01)

Treatment of Vietnamese patients diagnosed with myelodysplastic neoplasms: Practical experience in a developing country
by: Quang Hao Nguyen, et al.
Published: (2025-01-01)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
by: Fieke W. Hoff, et al.
Published: (2023-02-01)

Myelodysplastic syndromes: Where do we stand?
by: Nitin Sood, et al.
Published: (2016-01-01)

Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure
by: Abigail Belasen, et al.
Published: (2020-07-01)

Myelodysplastic syndrome from theoretical review to clinical application view
by: Amrallah A. Mohammad
Published: (2018-12-01)

Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa
by: Anna Jonasova, et al.
Published: (2024-10-01)

Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
by: Daniel Karel, et al.
Published: (2024-04-01)

Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count
by: Marion Divoux, et al.
Published: (2020-09-01)

New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome
by: E. V. Morozova, et al.
Published: (2022-11-01)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
by: Eleftheria Hatzimichael, et al.
Published: (2022-10-01)

Acute kidney injury with extreme hyperuricemia after antithymocyte globulin treatment in a kidney transplant recipient with underlying aplastic anemia: a case report
by: Yohan Park, et al.
Published: (2020-07-01)

Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge
by: Francesco Pisani, et al.
Published: (2014-04-01)

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial
by: Hui Liu, et al.
Published: (2023-07-01)

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
by: Yunshuo Xiao, et al.
Published: (2024-12-01)

Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review
by: Bruno Mendes, et al.
Published: (2022-08-01)

Long-term outcome of 25 children and adolescents with severe aplastic anemia treated with antithymocyte globulin
by: de-Medeiros C.R., et al.
Published: (2000-01-01)

Evolution of Immune Checkpoint Blockade–Induced Myocarditis Over 2 Years
by: Timothy G. Norwood, et al.
Published: (2020-02-01)

Hypomethylation of MIR‐378 5’‐flanking region predicts poor survival in young patients with myelodysplastic syndrome
by: De‐hong Wu, et al.
Published: (2020-01-01)

Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes
by: Vincent Jachiet, et al.
Published: (2021-05-01)

Therapeutic Options in Myelodysplastic Syndromes: Established and Emerging Therapies
by: Nina Kim, et al.
Published: (2018-08-01)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
by: Wang Eunice S, et al.
Published: (2012-11-01)

Agentes imunossupressores, talidomida e ácido valpróico nas síndromes mielodisplásicas Immunosuppressive agents, thalidomide and valproate acid in myelodysplastic syndromes
by: Elvira R. P. Velloso
Published: (2006-09-01)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
by: Guangjie Zhao, et al.
Published: (2021-09-01)

Long-term hematologic response after azacitidine treatment in a lower-risk myelodysplastic syndrome patient: A case report
by: Konstantinos Loukidis, et al.
Published: (2024-01-01)

The consensus on the diagnosis and treatment of elderly myelodysplastic neoplasm in China (2024)
by: MDS Professional Committee of Hematology Branch of Chinese Geriatrics Society
Published: (2024-06-01)

Successful desensitization to horse antithymocyte globulin for aplastic anemia: two case reports and literature review
by: Satoshi Yuyama, et al.
Published: (2025-02-01)

Acquired severe aplastic anemia treated with antithymocyte globulin and cyclosporine: An experience of regional cancer center, Western India
by: Ankit B Patel, et al.
Published: (2015-01-01)

Relationship between Post-kidney Transplantation Antithymocyte Globulin Therapy and Wound Healing Complications
by: G. R. Pourmand, et al.
Published: (2012-04-01)

Role of antithymocyte globulin in reducing the incidence of complications after allogeneic hemopoietic cell transplantation
by: Yu R Zalyalov, et al.
Published: (2010-08-01)

Outcome of therapy-related myeloid neoplasms treated with azacitidine
by: Fianchi Luana, et al.
Published: (2012-08-01)

The immunobiology of myelodysplastic neoplasms: a mini-review
by: Shruthi Kannan, et al.
Published: (2024-09-01)

Development of the treatment preference in myelodysplasia questionnaire for clinicians, carers, and patients
by: Robert Morlock, et al.
Published: (2024-06-01)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
by: Ziqi Wan, et al.
Published: (2020-10-01)

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
by: Pierre Fenaux, et al.
Published: (2017-06-01)

The mesenchymal compartment in myelodysplastic syndrome: Its role in the pathogenesis of the disorder and its therapeutic targeting
by: Charalampos G. Pontikoglou, et al.
Published: (2023-01-01)

A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients
by: Ludan Zhang, et al.
Published: (2024-05-01)

A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms
by: Rami Abdulbaki, et al.
Published: (2024-04-01)